Foley Partner David Rosen was quoted in an article that appeared in Genetic Engineering & Biotechnology News on October 12, 2011 titled “Extent of Feedback on RUO/IUO In Vitro Dx Draft Guidance Means Changes Not Expected Soon.” Rosen discusses draft guidance proposed by the FDA concerning the labeling of in vitro diagnostic (IVD) products marked “for research use only” (RUO) and “for investigational use only” (IUO). He states that some companies are concerned about what products they can sell as RUO/IUO tests and what they cannot under the FDA’s draft guidelines. Rosen recognizes the need for research, but notes that it is also important to ensure that people do not rely on tests that are not verified and validated.
People
Related News
July 2, 2025
In the News
John Strom and Peter Tomasi Quoted on Shift in Environmental Policy
Foley & Lardner LLP attorneys John Strom and Peter Tomasi commented on changes to federal environmental rules in the Utility Dive article, "Federal agencies, including FERC and DOE, revoke environmental review rules."
June 30, 2025
In the News
Lynn Gandhi Assesses Midyear Takeaways from Major State and Local Tax Cases
Foley & Lardner LLP partner Lynn Gandhi is featured by Law360 for her takeaways on major state and local tax cases in the article, "Top State & Local Tax Cases Of 2025: Midyear Report."
June 27, 2025
In the News
Donald Schroeder Highlights FMCS Importance Amid Service's Uncertain Future
Foley & Lardner LLP partner Donald Schroeder described the Federal Mediation and Conciliation Services' (FMCS) importance in the Law360 article, "As Feds' Bargaining Mediator Ails, New Services Emerge."